Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 202671
Company: MYLAN LABS LTD

Products on ANDA 202671

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
IBANDRONATE SODIUM	IBANDRONATE SODIUM	EQ 3MG BASE/3ML	INJECTABLE;INTRAVENOUS	Prescription	AP	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 202671

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
09/02/2014	ORIG-1	Approval				Label is not available on this site.

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
04/06/2018	SUPPL-4	Labeling-Container/Carton Labels, Labeling-Package Insert		Label is not available on this site.
04/06/2018	SUPPL-2	Labeling-Package Insert		Label is not available on this site.
09/02/2015	SUPPL-1	Labeling-Package Insert		Label is not available on this site.

Therapeutic Equivalents for ANDA 202671

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS; EQ 3MG BASE/3ML
TE Code = AP

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
IBANDRONATE SODIUM	IBANDRONATE SODIUM	EQ 3MG BASE/3ML	INJECTABLE;INTRAVENOUS	Prescription	No	AP	206058	ACCORD HLTHCARE
IBANDRONATE SODIUM	IBANDRONATE SODIUM	EQ 3MG BASE/3ML	INJECTABLE;INTRAVENOUS	Prescription	No	AP	204222	APOTEX
IBANDRONATE SODIUM	IBANDRONATE SODIUM	EQ 3MG BASE/3ML	INJECTABLE;INTRAVENOUS	Prescription	No	AP	205332	EUGIA PHARMA
IBANDRONATE SODIUM	IBANDRONATE SODIUM	EQ 3MG BASE/3ML	INJECTABLE;INTRAVENOUS	Prescription	No	AP	202671	MYLAN LABS LTD
IBANDRONATE SODIUM	IBANDRONATE SODIUM	EQ 3MG BASE/3ML	INJECTABLE;INTRAVENOUS	Prescription	No	AP	202235	SAGENT PHARMS INC
IBANDRONATE SODIUM	IBANDRONATE SODIUM	EQ 3MG BASE/3ML	INJECTABLE;INTRAVENOUS	Prescription	No	AP	090853	SUN PHARM